Phenotypic data from 328,973 participants enrolled in SPARK, including 132,138 individuals with ASD, are now available to approved researchers. Genomic data also is available for 116,693 SPARK participants, specifically 106,744 (44,304 ASD) with whole exome sequencing, and 12,519 (3,575 ASD) with whole genome sequencing. A total of 2,570 individuals have both.
A SFARI initiated and funded reanalysis of previous studies reveals consistent biological signals in the human microbiome and other physiological signals associated with autism and highlights the need for long-term studies to determine autism’s underlying causes.
SFARI is pleased to announce that it intends to fund 15 grants in response to the 2022 Genomics of ASD: Pathways to Genetic Therapies request for applications.
The Simons Foundation is now accepting applications from undergraduate students to participate in the Shenoy Undergraduate Research Fellowship in Neuroscience, or SURFiN, for the 2023–2024 academic year. The program’s goal is to spark and sustain interest in neuroscience among undergraduate students from diverse backgrounds underrepresented in neuroscience research. SURFiN is a joint initiative from the Simons Collaboration on the Global Brain (SCGB), the Simons Collaboration on Plasticity and the Aging Brain (SCPAB) and the Simons Foundation Autism Research Initiative (SFARI).
Phenotypic data from 310,649 participants enrolled in SPARK, including 123,444 individuals with ASD, are now available to approved researchers. Genomic data (whole-exome sequencing and genome-wide genotyping data) are also available for 81,172 SPARK participants. Of these, 3,568 genomes and 34,164 exomes are from individuals with ASD.
SFARI is pleased to announce that it intends to award ten grants in response to the 2022 Human Cognitive and Behavioral Science request for applications.
SFARI is pleased to announce that it intends to fund 16 grants in response to the 2022 Pilot Award request for applications.
New zebrafish lines with mutations in the high-confidence autism risk genes DYRK1A and GRIN2B have been added to SFARI resources.
Phenotypic data from 296,307 participants enrolled in SPARK, including 117,203 individuals with ASD, are now available to approved researchers. Genomic data (whole-exome sequencing and genome-wide genotyping data) are also available for 81,172 SPARK participants. Of these, 3,568 genomes and 34,164 exomes are from individuals with ASD.
Clinical Research Associates, L.L.C., an affiliate of the Simons Foundation, has recently launched a randomized controlled trial to test the safety, tolerability and efficacy of arbaclofen in 16p11.2 BP4-BP5 deletion syndrome.